Skip to main content

Month: June 2023

The Healing Company Reports Record Revenue and Provides Business Update for the Fiscal Third Quarter of 2023

Achieves revenue of $3.2 million for the third quarter of 2023, a 34.2% sequential increase over the second quarter of 2023 Completes acquisition of the Chopra Global wellbeing experiences businesses NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) — The Healing Company (OTC: HLCO) today provided a business update and reported financial results for the fiscal third quarter ended March 31, 2023.   Simon Belsham, CEO and Co-founder of The Healing Company, commented, “I am pleased to report we are making rapid progress on our strategy to establish The Healing Company as a leading global provider of integrated healing products, with a focus on the wellness, supplement, and nutraceutical markets. During the third quarter, we achieved record revenue of $3.2 million. Sequentially, our revenue increased 34% from the second quarter 2022. At the...

Continue reading

IR-Med Appoints Dr. Lynn Eschenbacher to its Advisory Board as Company Advances Toward Launch of its PressureSafe Wound Care Device

IR-MED Inc. Dr. Lynn EschenbacherInnovative executive driving positive outcomes and profitability, Dr. Eschenbacher is focused on addressing healthcare access and equity Through early, non-invasive detection of pressure injuries, PressureSafe is poised to save billions in acute care costs and reduce patient deaths from pressure woundsRosh Pina, Israel, June 07, 2023 (GLOBE NEWSWIRE) — IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive AI-driven spectrographic analysis technology platform to address significant healthcare needs, announced today the appointment of Lynn Eschenbacher PharmD, MBA, FASHP, CPEL to its Advisory Board. Dr. Eschenbacher is an innovative business development executive with extensive experience in the healthcare industry. As CEO and Founder of Echelon Health Strategies,...

Continue reading

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Secondary Efficacy Analyses, Including of Neuromuscular Blockade and Spontaneous Reversal, Support Earlier Reported Clinical Results with BX1000 MALVERN, Pa., June 07, 2023 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, today announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Additional analyses of electromyography (EMG) of neuromuscular blockade confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium. The BX1000 Phase 2 surgery trial was a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a...

Continue reading

Verizon lights up 5G Ultra Wideband across Indiana

Customers in St. Joseph, Kosciusko, South Bend, Elkhart, Goshen, Nappanee, LaGrange, and Warsaw benefit from new high-performance 5G technology with higher speeds, greater capacity and network reliability SOUTH BEND, Ind., June 07, 2023 (GLOBE NEWSWIRE) — Residents across St. Joseph, Kosciusko, South Bend, Elkhart, Goshen, Nappanee, LaGrange, and Warsaw, Indiana now have access to higher speeds and greater capacity from Verizon’s award-winning 5G network. Verizon’s 5G Ultra Wideband brings power and performance comparable to a wired broadband internet connection to customers’ pockets. Verizon’s 5G Ultra Wideband enables people to do things on their mobile device that many could only do before when connected to their home internet service. This includes everything from downloading huge documents and streaming movies in HD...

Continue reading

AppFolio Launches Innovative AI Capabilities and Affordable Housing Solution to Empower Property Managers, Enhance Resident Experiences

Groundbreaking additions to AppFolio Property Manager accompanied by the expansion of its Stack MarketplaceAppFolio Realm AI Leasing Assistant, Lisa and Smart Bill Entry are part of a suite of AI-powered features within AppFolio Realm, delivering on its product vision to create a world where managing communities feels magical and effortless.AppFolio Realm Conversational Interface New innovations like a conversational interface, currently being piloted with a select group of trusted users, leverage the power of large language models (LLMs).SANTA BARBARA, Calif., June 07, 2023 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ:APPF), a cloud-based technology platform built for the real estate industry, today introduced a host of new capabilities to better serve property management customers and their residents. Innovations include...

Continue reading

GD Culture Group Limited Participates and Presents at BitBlock Summit Held in New York City on June 1, 2023

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) — GD Culture Group Limited (“GDC” or the “Company”), a holding company currently conducting business through Shanghai Highlight Media Co., Ltd. (“Highlight Media”) today announced that Mr. Xiaojian Wang, the Chief Executive Officer of the Company, participated and presented in the panel discussion of “Can Web3 Accelerate the Advancement of AI” at BitBlock Summit (the “Summit”) held in New York City on June 1, 2023. About BitBlock Summit BitBlock Summit, which is held twice a year worldwide, gather the world’s top AI & Web3.0 leaders from the industry, government authorities, scientists, investors, and related organizations. This year, the main theme is “AI & Web 3.0 “, aimed to explore the cutting-edge of Web3.0 technologies and investment hotspots....

Continue reading

Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023

SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that it will present interim data from the FASCINATE-2 Phase 2b clinical trial of its lead product candidate, denifanstat, a fatty acid synthase (FASN) inhibitor, in nonalcoholic steatohepatitis (NASH) at the European Association for the Study of the Liver (EASL) Congress. The event will be held in Vienna, Austria from June 21-24, 2023. Details of the presentation are as follows: Abstract Title: Multicenter, randomized, double-blind, placebo-controlled trial of Fatty Acid Synthase (FASN) inhibitor, denifanstat, versus placebo in the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial.Abstract...

Continue reading

A Surprisingly High Number of Americans Think Insurance Fraud Is Not a Crime, New Survey Shows

Younger generations are more tolerant of fraud and ‘envious’ of those who commit it JERSEY CITY, N.J., June 07, 2023 (GLOBE NEWSWIRE) — A significant number of Americans aged 45 and younger show a high level of tolerance for insurance fraud – even feeling envious of those who commit it – according to a new survey of insurance consumers by Verisk (Nasdaq: VRSK) and the Coalition Against Insurance Fraud. The study analyzes how American consumers view insurance fraud and insurance crime and delves into the psychology of insurance fraud to understand the motivations and justification for the crime derived from in-depth interviews with those convicted of insurance fraud. “This study should sound the alarm for insurers, consumer activists, regulators, and legislators on the state of fraud in America. While it’s marginally reassuring...

Continue reading

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

WOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific poster was titled “Abnormal combined diabetic peripheral neuropathy (DPN)-check and SUDOSCAN results predict all-cause mortality in people with diabetes: The Sheffield prospective study.” The study prospectively followed 245 individuals with diabetes for 7-years following screening for peripheral neuropathy. The screening tests included a structured clinical exam (Toronto Clinical Neuropathy Score, TCNS), the Semmes-Weinstein Monofilament test (10 g-MFT) that is a subjective, clinical test for DPN, a device (Sudoscan®) that measures autonomic nerve function, and DPNCheck. DPNCheck and Sudoscan are complementary validated...

Continue reading

Snowmobile Market Size Worth USD 2.85 Billion, Globally, by 2030 at a CAGR of 4.7%

Snowmobile Market to Experience CAGR of 4.7% during 2023-2030; Shift toward Electrification to Drive Market Growth Pune, June 07, 2023 (GLOBE NEWSWIRE) — The global snowmobile market size was valued at USD 1.70 billion in 2022. The market is projected to grow from USD 1.80 billion in 2023 to USD 2.85 billion by 2030, growing at a CAGR of 4.7% over the forecast period. A motorized recreational vehicle specially designed for winter sports activities or recreation on snow is called a snowmobile or Ski-Doo or skimobile, or snow scooter. The vehicle can be used on snow and it does not require any trail or road, of which most are driven on open terrain or trail. Fortune Business Insights provide this information in its report titled “Snowmobile Market, 2023-2030.” Request a Free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/snowmobile-market-107554 Report...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.